Isolation of glucagon antagonists by random molecular mutagenesis and screening

RA Smith, R Sisk, P Lockhart, S Mathewes, T Gilbert, K Walker and J Piggot

Zymogenetics, Inc., Seattle, Washington 98105.

Glucagon has an important role in the regulation of glucose homeostasis, and glucagon antagonists may be effective therapeutic agents in the control of diabetes mellitus. We were able to identify a number of analogs with antagonist activity by creating libraries of mutant glucagon coding sequences, expressing them in a yeast (Saccharomyces cerevisiae) secretion system, and screening for clones that produce analogs that inhibit the glucagon stimulation of rat hepatocyte membrane adenylate cyclase. These libraries were constructed by allowing random misincorporation during the synthesis of oligonucleotides that contained the complete coding sequence for mammalian glucagon or for an analog (desHis1-glucagon) that had partial antagonist activity. We developed and used a simplified screening assay to test culture broths from > 3500 individual transformant yeast clones for their ability to inhibit glucagon-dependent adenylate cyclase activity. Ultimately, > 20 different analogs with antagonist activity were identified by recovering and sequencing plasmid DNA from yeast strains that were positive in the screening assay. Interestingly, several analogs were identified repeatedly in independent yeast clones and certain amino acid substitutions occurred in more than one analog. This clustering of randomly isolated mutations clearly delineates the regions of the glucagon molecule that are important for designing improved glucagon antagonists. A subset of the antagonists identified in yeast broth were produced by peptide synthesis to confirm their activities as pure compounds.

Volume 43, Issue 5, pp. 741-748, 05/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. Q. Pan, J. M. Buxton, S. L. Yung, I. Tom, L. Yang, H. Chen, M. MacDougall, A. Bell, T. H. Claus, K. B. Clairmont, et al. Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist J. Biol. Chem., May 5, 2006; 281(18): 12506 - 12515. [Abstract] [Full Text] [PDF]

				S. A. Hinke, J. A. Pospisilik, H.-U. Demuth, S. Mannhart, K. Kuhn-Wache, T. Hoffmann, E. Nishimura, R. A. Pederson, and C. H. S. McIntosh Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon. CHARACTERIZATION OF GLUCAGON DEGRADATION PRODUCTS AND DPIV-RESISTANT ANALOGS J. Biol. Chem., February 11, 2000; 275(6): 3827 - 3834. [Abstract] [Full Text] [PDF]

				P. Shah, A. Basu, R. Basu, and R. Rizza Impact of lack of suppression of glucagon on glucose tolerance in humans Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E283 - E290. [Abstract] [Full Text] [PDF]